| 2025 |
Wong, S., Selby, P. R., Ward, M. B., & Reuter, S. E. (2025). Exploring health care professionals' engagement with a precision dosing calculator and supporting clinical information: insights from an eye-tracking and usability study. Therapeutic Drug Monitoring, online(6), 1-10. DOI |
| 2025 |
Janetzki, J., Johnson, J., Kalisch Ellett, L., Ho, J. N., Hall, K., Ward, M., & Pratt, N. (2025). Effect and illustrative costs of downscheduling on government subsidised dispensings of triptans in Australia: a 10-year analysis. Australian Health Review, 49(4, article no. AH25050), 1-7. DOI |
| 2025 |
Azroun, R., Ellett, L. K., Pratt, N., Ward, M., & Janetzki, J. (2025). National Response to Warfarin Shortages: evaluating Regulatory Substitution and Notified Shortages and Their Effects on Antithrombotic Dispensings, Pathology Monitoring and Adverse Event Trends in Australia. Drug Safety, online, 11 pages. DOI |
| 2025 |
Janetzki, J., Cornelius-Bell, A., & Ward, M. (2025). Understanding Physiotherapy student’s opinions on the importance of pharmacology and style of pharmacology assessments in preparation for future practice. Physical Therapy Reviews, 30(1), 18-27. DOI |
| 2025 |
Kalisch Ellett, L. M., Janetzki, J. L., Suppiah, V., Chai, W., Staff, K., Amato, D., . . . Ward, M. B. (2025). Quantifying the non-remunerated services provided by pharmacists in community pharmacies: a direct observational study. International Journal of Pharmacy Practice, online, 1-8. DOI |
| 2025 |
Hillen, J. B., Stanford, T., Ward, M., Duszynski, K., Tong, X., Li, S. X., . . . Pratt, N. (2025). Medicines Policy in Action: The Impact on Volume and Cost of Biologic Medicines After Biosimilar Introduction. Value in Health Regional Issues, 50(101173), 7 pages. DOI |
| 2025 |
Tan, M. S., Patel, B. K., Roughead, E. E., Ward, M., Reuter, S. E., Roberts, G., & Andrade, A. Q. (2025). Opportunities for clinical decision support targeting medication safety in remote primary care management of chronic kidney disease: a qualitative study in Northern Australia. Journal of Telemedicine and Telecare, 31(5), 656-666. DOI |
| 2024 |
Janetzki, J., Sykes, M., Ward, M., & Pratt, N. (2024). Chronic Obstructive Pulmonary Disease adverse event signals associated with potential inhibitors of glutathione peroxidase 1: a sequence symmetry analysis. Drug Safety, 47(1), 59-70. DOI Scopus1 |
| 2024 |
Larcombe, R., Coulthard, K., Eaton, V., Tai, A., Reuter, S., & Ward, M. (2024). Is there a multinational consensus of tobramycin prescribing and monitoring for cystic fibrosis? Survey of current therapeutic drug monitoring practices in USA/Canada, UK/Ireland, and Australia/New Zealand. European Journal of Hospital Pharmacy, 31(4), 301-306. DOI Scopus2 WoS2 |
| 2024 |
Tait, K., Gandhi, J., Ward, M., Calabretto, J. P., & Rossi, S. (2024). Student evaluation of an instructional video on how to use a national medicines information resource. International Journal of Pharmacy Practice, 32(3), 251-255. DOI |
| 2023 |
Peng, K., Blais, J. E., Pratt, N. L., Guo, J. J., Hillen, J. B., Stanford, T., . . . Li, X. (2023). Impact of introducing infliximab biosimilars on total infliximab consumption and originator infliximab prices in eight regions: an interrupted time-series analysis. BioDrugs, 37(3), 409-420. DOI Scopus10 WoS11 Europe PMC6 |
| 2023 |
Janetzki, J. L., Pratt, N. L., Ward, M. B., & Sykes, M. J. (2023). Application of an integrative drug safety model for detection of adverse drug events associated with inhibition of glutathione peroxidase 1 in chronic obstructive pulmonary disease. Pharmaceutical Research, 40(6), 1553-1568. DOI Scopus3 WoS2 Europe PMC3 |
| 2023 |
Wong, S., Davis, A., Selby, P. R., Khoo, R., Gwilt, I., Stocker, S. L., . . . Reuter, S. E. (2023). Application of user-centered co-design principles to address barriers in therapeutic drug monitoring.. Therapeutic drug monitoring, 45(3), 368-375. DOI Scopus4 WoS4 Europe PMC5 |
| 2023 |
Tong, X., Shen, C. Y., Jeon, H. L., Li, Y., Shin, J. Y., Chan, S. C. W., . . . Lai, E. C. C. (2023). Cardiovascular risk in rheumatoid arthritis patients treated with targeted synthetic and biological disease-modifying antirheumatic drugs: a multi-centre cohort study. Journal Of Internal Medicine, 294(3), 314-325. DOI Scopus17 WoS18 Europe PMC18 |
| 2022 |
Tong, X., Li, X., Pratt, N. L., Hillen, J. B., Stanford, T., Ward, M., . . . Wong, I. C. K. (2022). Monoclonal antibodies and Fc-fusion protein biologic medicines: a multinational cross-sectional investigation of accessibility and affordability in Asia Pacific regions between 2010 and 2020. Lancet Regional Health-Western Pacific, 26(100506), 1-12. DOI Scopus19 WoS16 Europe PMC14 |
| 2022 |
Hillen, J., Ward, M., Slee, M., Stanford, T., Roughead, E., Kalisch Ellett, L., & Pratt, N. (2022). Utilisation of disease modifying treatment and diversity of treatment pathways in relapsing remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 57(article no. 103412), 8 pages. DOI Scopus3 WoS3 Europe PMC3 |
| 2022 |
Kelly, T. L., Ward, M., Pratt, N. L., Ramsay, E., Gillam, M., & Roughead, E. E. (2022). The association between exacerbation of chronic obstructive pulmonary disease and timing of paracetamol use: a cohort study in elderly Australians. Respiratory Research, 23(1), 11 pages. DOI Scopus3 WoS3 Europe PMC3 |
| 2022 |
Hillen, J. B., Stanford, T., Ward, M., Roughead, E. E., Kalisch-Ellett, L., & Pratt, N. (2022). Rituximab and Pyoderma Gangrenosum: An Investigation of Disproportionality Using a Systems Biology-Informed Approach in the FAERS Database. Drugs Real World Outcomes, 9(4), 639-647. DOI Scopus3 WoS2 Europe PMC3 |
| 2022 |
Putnikovic, M., Jordan, Z., Munn, Z., Borg, C., & Ward, M. (2022). Use of Electrocardiogram monitoring in adult patients taking high-risk QT interval prolonging medicines in Clinical Practice: systematic review and meta-analysis. Drug Safety, 45(10), 1037-1048. DOI Scopus6 WoS6 Europe PMC6 |
| 2021 |
De Vries, C., Gadzhanova, S., Sykes, M. J., Ward, M., & Roughead, E. (2021). A systematic review and meta-analysis considering the risk for congenital heart defects of antidepressant classes and individual antidepressants. Drug Safety, 44(3), 291-312. DOI Scopus42 WoS34 Europe PMC23 |
| 2021 |
Janetzki, J. L., Sykes, M. J., & Ward, M. B. (2021). Proton pump inhibitors may contribute to progression or development of chronic obstructive pulmonary disease-a sequence symmetry analysis approach. Journal of Clinical Pharmacy and Therapeutics, 46(6), 1687-1694. DOI Scopus9 WoS6 Europe PMC6 |
| 2021 |
Lambert, R., Burgess, N., Hillock, N., Gailer, J., Hissaria, P., Merlin, T., . . . Hill, C. (2021). South Australian Medicines Evaluation Panel in review: providing evidence-based guidance on the use of high-cost medicines in the South Australian public health system. Australian Health Review, 45(2), 207-213. DOI |
| 2021 |
Putnikovic, M., Ward, M., & Jordan, Z. (2021). Use of ECG monitoring for adult patients taking high-risk QT interval-prolonging drugs in clinical practice: a systematic review protocol. JBI evidence synthesis, 19(11), 3113-3120. DOI Scopus1 WoS2 Europe PMC1 |
| 2021 |
Reuter, S. E., Schultz, H. B., Ward, M. B., Grant, C. L., Paech, G. M., Banks, S., & Evans, A. M. (2021). The effect of high-dose, short-term caffeine intake on the renal clearance of calcium, sodium and creatinine in healthy adults. British Journal of Clinical Pharmacology, 87(11), 4461-4466. DOI Scopus15 WoS13 Europe PMC13 |
| 2021 |
Menz, B., Johnson, J. L., Gillard, D. F., Chong, W., & Ward, M. B. (2021). The role of the pharmacist in optimizing cancer immunotherapy: a retrospective study of nivolumab adverse events. Journal of pharmacy practice, 34(3), 386-396. DOI |
| 2019 |
Reuter, S. E., Evans, A. M., & Ward, M. B. (2019). Reducing palivizumab dose requirements through rational dose regimen design. CPT: pharmacometrics and systems pharmacology, 8(1), 26-33. DOI Scopus3 WoS4 Europe PMC6 |
| 2019 |
Eldi, P., Cooper, T., Ward, M., & Hayball, J. D. (2019). How emerging vaccine technologies are pushing disease prevention boundaries. International pharmacy journal, 37(1), 16-19. |
| 2018 |
Prosser, A. E., Dawson, J. L., Koo, K., O'Kane, K. M., Ward, M. B., Woodman, R. J., . . . Phillips, C. J. (2018). Real-world incidence of patient-reported dyspnoea with ticagrelor. Therapeutic advances in drug safety, 9(10), 577-584. DOI |
| 2018 |
Caughey, G. E., Gabb, G., Ronson, S., Ward, M., Hill, C., Beukelman, T. G., & Limaye, V. (2018). Association of Statin Exposure with Histologically-Confirmed Idiopathic Inflammatory Myositis in an Australian Population. JAMA Internal Medicine, 178(9), 1224-1229. DOI Scopus21 WoS21 Europe PMC16 |
| 2018 |
Petito, E. S., Foster, D. J. R., Ward, M. B., & Sykes, M. J. (2018). Molecular modeling approaches for the prediction of selected pharmacokinetic properties. Current topics in medicinal chemistry, 18(26), 2230-2238. DOI Scopus2 WoS2 Europe PMC1 |
| 2017 |
Turkanovic, J., Ward, M. B., Gerber, J. P., & Milne, R. W. (2017). Effect of garlic, gingko, and St. John's wort extracts on the pharmacokinetics of fexofenadine: a mechanistic study. Drug metabolism and disposition, 45(5), 569-575. DOI |
| 2016 |
Ward, M. B., Reuter, S. E., & Martin, J. H. (2016). How 'optimal' are optimal sampling times for tyrosine kinase inhibitors in cancer? Practical considerations. Clinical pharmacokinetics, 55(10), 1171-1177. DOI |
| 2016 |
McKinnon, R. A., & Ward, M. B. (2016). Biological medicines (biologics) and biosimilars. Australian journal of pharmacy, 97(1152), 87-91. |
| 2016 |
Shin, H. Y., Gadzhanova, S., Roughead, E. E., Ward, M. B., & Pont, L. G. (2016). The use of antipsychotics among people treated with medications for dementia in residential aged care facilities. International Psychogeriatrics, 28(6), 977-982. DOI Scopus12 WoS13 Europe PMC12 |
| 2016 |
McKinnon, R., & Ward, M. (2016). Safety considerations of biosimilars. Australian Prescriber, 39(6), 188-189. DOI Europe PMC6 |
| 2016 |
Tucker, G., DeSilva, B., Dressman, J., Ito, M., Kumamoto, T., Mager, D., . . . Ward, M. (2016). Current challenges and potential opportunities for the pharmaceutical sciences to make global impact: an FIP perspective. Journal of pharmaceutical sciences, 105(9), 2489-2497. DOI WoS22 Europe PMC12 |
| 2015 |
Kershaw, S., Della Vedova, C., Majumder, I., Ward, M., Farquharson, A., Williamson, P., & White, J. (2015). Acute opioid administration induces hypothalamic-pituitary-adrenal activation and is mediated by genetic variation in interleukin (Il)1B. Pharmacology, Biochemistry and Behavior, 138, 9-13. DOI Scopus6 WoS6 Europe PMC6 |
| 2015 |
Sluggett, J., Caughey, G., Ward, M., & Gilbert, A. (2015). Medicines taken by older Australians after transient ischaemic attack or ischaemic stroke: a retrospective database study. International Journal of Clinical Pharmacy, 37(5), 782-789. DOI Scopus5 WoS3 Europe PMC3 |
| 2015 |
Kershaw, S. G., Dry, M., Della Vedova, C., Majumder, I., Ward, M., Williamson, P., & White, J. (2015). Inspection time as a general measure of cognitive impairment following acute opioid exposure. Drug and Alcohol Dependence, 156, e108. DOI |
| 2014 |
Westley, I., Coller, J., Ward, M., Evans, A., Morris, R., & Sallustio, B. (2014). A primer extension denaturing high-performance liquid chromatography method for the identification of three ABCC2 genetic polymorphisms. Journal of Liquid Chromatography and Related Technologies, 37(9), 1249-1256. DOI |
| 2014 |
Sluggett, J., Caughey, G., Ward, M., & Gilbert, A. (2014). Use of secondary stroke prevention medicines in Australia: National trends, 2003-2009. Medical Journal of Australia, 201(1), 54-57. DOI Scopus7 WoS6 Europe PMC6 |
| 2014 |
Sluggett, J. K., Caughey, G. E., Ward, M. B., & Gilbert, A. L. (2014). Doubling the use of alteplase in Australia between 2003 and 2009. International journal of stroke, 9(6), 28. DOI |
| 2014 |
Sluggett, J., Caughey, G., Ward, M., & Gilbert, A. (2014). Antithrombotic use following transient ischaemic attack or ischaemic stroke among older Australians with atrial fibrillation. Internal Medicine Journal, 44(11), 1134-1137. DOI Scopus1 WoS1 Europe PMC1 |
| 2013 |
Sluggett, J. K., Caughey, G. E., Ward, M. B., Roughead, E. E., & Gilbert, A. L. (2013). Transient ischaemic attack and ischaemic stroke : constructing episodes of care using hospital claims data. BMC research notes, 6(128), 1-6. DOI Scopus8 Europe PMC7 |
| 2012 |
Dias, M., Depala, K., Ward, H., Ward, M., Sorich, M., Anderson, C., & McKinnon, R. (2012). Reforming pharmaceutical education to enhance the global uptake of pharmacogenenomics and personalized medicine. Current pharmacogenomics and personalized medicine, 10(3), 231-238. DOI Scopus3 |
| 2012 |
Anderson, C., Ward, H., Corkindale, D., Ward, M., Sorich, M., & McKinnon, R. (2012). Pharmacogenomics and personalized medicine: consumer perspectives, lessons learned in Australia and beyond. Current pharmacogenomics and personalized medicine, 10(2), 170-177. DOI Scopus1 |
| 2012 |
Tran, M. D., Sharley, N., & Ward, M. (2012). Stability of amoxycillin, clindamycin and meropenem in peritoneal dialysis solution. Journal of pharmacy practice and research, 42(3), 218-222. |
| 2011 |
Sluggett, J. K., Ward, M. B., Caughey, G. E., & Gilbert, A. L. (2011). Pharmacotherapy for secondary prevention of transient ischaemic attack and ischaemic stroke in adults. Australian pharmacist, 30(3), 224-228. |
| 2011 |
Ward, M., & Foster, D. (2011). CYP2C19-guided design of a proton pump inhibitor dose regimen to avoid the need for pharmacogenetic individualisation in H. pylori eradication. European Journal of Clinical Pharmacology, 67(3), 261-266. DOI Scopus3 WoS3 Europe PMC3 |
| 2010 |
Plevin, D., Ward, H., Ward, M., Sorich, M., & McKinnon, R. (2010). Pharmacists' role in targeted cancer therapy in Australia and implications for pharmacy education. American Journal of Pharmaceutical Education, 74(9), Article 168 (6 pages). DOI Scopus6 WoS5 Europe PMC3 |
| 2010 |
Sorich, M., Vitry, A., Ward, M., Horowitz, J., & McKinnon, R. (2010). Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. Journal of Thrombosis and Haemostasis, 8(8), 1678-1684. DOI Scopus95 WoS79 Europe PMC73 |
| 2009 |
Ward, M. B., Sorich, M. J., Evans, A. M., & McKinnon, R. A. (2009). Cytochrome P450 part 3: Impact of drug-drug interactions. Journal of pharmacy practice and research, 39(1), 55-58. DOI Scopus5 |
| 2008 |
Ward, M. B., Sorich, M. J., & McKinnon, R. A. (2008). Cytochrome P450 Part 2: Genetics of Inter-Individual Variability. Journal of pharmacy practice and research, 38(3), 226-229. |
| 2008 |
McKinnon, R. A., Sorich, M. J., & Ward, M. B. (2008). Cytochrome P450 part1: multiplicity and function. Journal of pharmacy practice and research, 38(1), 55-57. |
| 2008 |
Ward, M., Kotasek, D., & McKinnon, R. (2008). Investigation of HTR3C mutations for association with 5HT3 receptor antagonist anti-emetic efficacy. Pharmagenomics, 9(8), 1027-1033. DOI Scopus15 WoS15 Europe PMC11 |
| 2007 |
McKinnon, R. A., Ward, M. B., & Sorich, M. J. (2007). A critical analysis of barriers to the clinical implementation of pharmacogenomics. Therapeutics and Clinical Risk Management. |